A Phase 2, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Trial Profile

A Phase 2, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs CNTO 2476 (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 13 Nov 2017 Status changed from not yet recruiting to discontinued.
    • 20 Mar 2017 Planned End Date changed from 1 Aug 2022 to 19 Aug 2022.
    • 20 Mar 2017 Planned primary completion date changed from 1 Feb 2021 to 20 Feb 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top